Your browser doesn't support javascript.
loading
The usage, quality and relevance of information and communications technologies in patients with chronic urticaria: A UCARE study.
Maurer, Marcus; Weller, Karsten; Magerl, Markus; Maurer, Rasmus Robin; Vanegas, Emanuel; Felix, Miguel; Cherrez, Annia; Mata, Valeria L; Kasperska-Zajac, Alicja; Sikora, Agnieszka; Fomina, Daria; Kovalkova, Elena; Godse, Kiran; Rao, Nimmagadda Dheeraj; Khoshkhui, Maryam; Rastgoo, Sahar; Criado, Roberta Fachini Jardim; Abuzakouk, Mohamed; Grandon, Deepa; van Doorn, Martijn; Valle, Solange Olliveira Rodrigues; de Souza Lima, Eduardo Magalhães; Thomsen, Simon Francis; Ramón, German D; Matos Benavides, Edgar E; Bauer, Andrea; Giménez-Arnau, Ana Maria; Kocatürk, Emek; Guillet, Carole; Ignacio Larco, Jose; Zhao, Zuo-Tao; Makris, Michael; Ritchie, Carla; Xepapadaki, Paraskevi; Ensina, Luis Felipe; Cherrez, Sofia; Cherrez-Ojeda, Ivan.
Affiliation
  • Maurer M; Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Germany.
  • Weller K; Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Germany.
  • Magerl M; Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Germany.
  • Maurer RR; Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Germany.
  • Vanegas E; Universidad Espíritu Santo, Samborondón, Ecuador.
  • Felix M; Respiralab, Respiralab Research Group, Guayaquil, Ecuador.
  • Cherrez A; Universidad Espíritu Santo, Samborondón, Ecuador.
  • Mata VL; Respiralab, Respiralab Research Group, Guayaquil, Ecuador.
  • Kasperska-Zajac A; Respiralab, Respiralab Research Group, Guayaquil, Ecuador.
  • Sikora A; Clinic and Policlinic for Dermatology and Venereology, University Medical Center Rostock, Rostock, Germany.
  • Fomina D; Universidad Espíritu Santo, Samborondón, Ecuador.
  • Kovalkova E; Respiralab, Respiralab Research Group, Guayaquil, Ecuador.
  • Godse K; European Center for Diagnosis and Treatment of Urticaria, Medical University of Silesia, Katowice, Poland.
  • Rao ND; European Center for Diagnosis and Treatment of Urticaria, Medical University of Silesia, Katowice, Poland.
  • Khoshkhui M; City Center of Allergy and Immunology, Clinical City Hospital #52, Moscow, Russia.
  • Rastgoo S; Department of Allergology and Clinical Immunology, I.M. Sechenov First Moscow State Medical University, Trubetskaya St., 8/2, Moscow, 119991, Russian Federation.
  • Criado RFJ; City Center of Allergy and Immunology, Clinical City Hospital #52, Moscow, Russia.
  • Abuzakouk M; Department of Dermatology, D Y, Patil University School of Medicine and Hospital, Mumbai, India.
  • Grandon D; Department of Dermatology, D Y, Patil University School of Medicine and Hospital, Mumbai, India.
  • van Doorn M; Allergy Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Valle SOR; Department of Allergy and Immunology, Mashhad University of Medical Sciences, Mashhad, Iran.
  • de Souza Lima EM; Department of Allergy and Immunology, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Thomsen SF; Department of Dermatology, Faculdade de Medicina do ABC, São Paulo, Brazil.
  • Ramón GD; Allergy and Immunology Department, Cleveland Clinic Abu Dhabi, The Uae.
  • Matos Benavides EE; Allergy and Immunology Department, Cleveland Clinic Abu Dhabi, The Uae.
  • Bauer A; Department of Dermatology, Erasmus MC, Rotterdam, the Netherlands.
  • Giménez-Arnau AM; Department of Internal Medicine, Hospital Universitário Clementino Fraga Filho, Rio de Janeiro, Brazil.
  • Kocatürk E; Faculty of Science and Health of Juiz de Fora - SUPREMA - Minas Gerais.
  • Guillet C; Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, Biomedical Sciences, Copenhagen, Denmark.
  • Ignacio Larco J; Instituto de Alergia e Inmunología del Sur, Bahía Blanca, De Buenos Aires, Argentina.
  • Zhao ZT; Centro de Referencia de Alergia, Asma e Inmunología - Instituto Nacional del Niño, Lima-Perú.
  • Makris M; Department of Dermatology, University Allergy Center, University Hospital Carl Gustav Carus, Technical University, Dresden, Germany.
  • Ritchie C; Department of Dermatology, Hospital del Mar, IMIM, Universitat Autònoma, Barcelona, Spain.
  • Xepapadaki P; Department of Dermatology, Koç University School of Medicine, Istanbul, Turkey.
  • Ensina LF; Department of Dermatology, University Hospital Zurich, Switzerland.
  • Cherrez S; Allergy Department, Clinica San Felipe, Lima, Peru.
  • Cherrez-Ojeda I; Department of Dermatology and Venereology, Peking University First Hospital, Beijing, China.
World Allergy Organ J ; 13(11): 100475, 2020 Nov.
Article in En | MEDLINE | ID: mdl-33204387
ABSTRACT

BACKGROUND:

Chronic urticaria (CU) is characterized by itchy recurrent wheals, angioedema, or both for 6 weeks or longer. CU can greatly impact patients' physical and emotional quality of life. Patients with chronic conditions are increasingly seeking information from information and communications technologies (ICTs) to manage their health. The objective of this study was to assess the frequency of usage and preference of ICTs from the perspective of patients with CU.

METHODS:

In this cross-sectional study, 1800 patients were recruited from primary healthcare centers, university hospitals or specialized clinics that form part of the UCARE (Urticaria Centers of Reference and Excellence) network throughout 16 countries. Patients were >12 years old and had physician-diagnosed chronic spontaneous urticaria (CSU) or chronic inducible urticaria (CIndU). Patients completed a 23-item questionnaire containing questions about ICT usage, including the type, frequency, preference, and quality, answers to which were recorded in a standardized database at each center. For analysis, ICTs were categorized into 3 groups as follows one-to-one SMS, WhatsApp, Skype, and email; one-to-many YouTube, web browsers, and blogs or forums; many-to-many Instagram, Twitter, Facebook, and LinkedIn.

RESULTS:

Overall, 99.6% of CU patients had access to ICT platforms and 96.7% had internet access. Daily, 85.4% patients used one-to-one ICT platforms most often, followed by one-to-many ICTs (75.5%) and many-to-many ICTs (59.2%). The daily ICT usage was highest for web browsers (72.7%) and WhatsApp (70.0%). The general usage of ICT platforms increased in patients with higher levels of education. One-to-many was the preferred ICT category for obtaining general health information (78.3%) and for CU-related information (75.4%). A web browser (77.6%) was by far the most commonly used ICT to obtain general health information, followed by YouTube (25.8%) and Facebook (16.3%). Similarly, for CU-specific information, 3 out of 4 patients (74.6%) used a web browser, 20.9% used YouTube, and 13.6% used Facebook. One in 5 (21.6%) patients did not use any form of ICT for obtaining information on CU. The quality of the information obtained from one-to-many ICTs was rated much more often as very interesting and of good quality for general health information (53.5%) and CU-related information (51.5%) as compared to the other categories.

CONCLUSIONS:

Usage of ICTs for health and CU-specific information is extremely high in all countries analyzed, with web browsers being the preferred ICT platform.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Observational_studies Aspects: Patient_preference Language: En Journal: World Allergy Organ J Year: 2020 Document type: Article Affiliation country: Germany

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Observational_studies Aspects: Patient_preference Language: En Journal: World Allergy Organ J Year: 2020 Document type: Article Affiliation country: Germany